- PLATFORM LOGINS
- |
- CONTACT
- Request a Demo
-
NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer
MUNICH &
“We continue to be on the cutting edge of cancer research and that,
coupled with the advancements we’re making in all areas of cancer
diagnostics, treatment plans and provider solutions, are all important
steps in supporting physicians and patients,” said Dr.
The oral presentation, Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation, authored by Y. Sunakawa, et al, includes investigational data suggesting that circulating DNA markers may predict outcomes in mCRC and can guide treatment decisions for these patients.
Additional papers were reviewed showing breakthroughs in immune oncology, including:
Title: Differential expression of PD-L1 and immune biomarkers by
age: Decreased expression in pediatric/AYA patients with advanced cancer
Author:
Dr.
Description: Whole exome and RNA
sequencing of 1,467 patients highlights younger patients (age <
24) with advanced cancer appear to have lower levels of CTLA4 and PD-L1
expression.
Key Takeaway: Immune checkpoint drugs have not
yet been approved in pediatric and adolescent/young adult patients.
Large dataset results show it may be necessary to employ new
combinations to be used in younger patients such as Nant’s Cancer
Vaccine, immunotherapy that combines the delivery of metronomic,
low-dose chemotherapy and radiation therapy with natural killer (NK)
cell-based technology to enhance patient’s immune system response
against cancer cells.
Title: PD-L1 expression is strongly associated with TIGIT, FOXP3
and LAG3 across advanced cancers, but not OX40, TIM3 and IDO
Author:
Dr.
Description: RNA sequencing
reveals immune checkpoint gene expression was not significantly
different in TMB high versus low groups. In patients demonstrating the
highest PD-L1 expression, higher expression of CTLA4, TIGIT, FOXP3 and
LAG3 were also observed.
Key Takeaway: While researchers are
focused on TMB as a more promising biomarker for Immuno-Oncology (IO)
therapy than PDL1, this research shows PDL1 may be a marker of
generalized tumor inflammation and could be the reason those tumors
respond to IO drugs.
Title: Predicting survival benefit of capecitabine plus cisplatin
in patients with metastatic gastric cancer using quantitative proteomics
Author:
Description: Targeted proteomic analysis of
metabolic enzymes required for intracellular activation of the
chemotherapeutic drug capecitabine identifies specific enzymes and
expression cutoffs which are significantly associated with extended
survival in metastatic gastric cancer patients given this drug regimen.
Key
Takeaway: Clinical tissue analysis of specific proteomic biomarkers
could be used to better personalize the usage of chemotherapeutic agents.
Title: Development and validation of neuroendocrine tumor marker
panel in small biopsies using multiplexed mass spectrometry
Author:
Description: Immunohistochemical
analysis of neuroendocrine tumor markers is performed on only a small
subset of cancer. In spite of the approval of several new agents with
specific activity against neuroendocrine tumors. A multiplexed clinical
tissue proteomics assay was developed to add analysis of neuroendocrine
markers into a larger diagnostic panel in order to better identify
candidates for neuroendocrine specific therapy.
Key Takeaway: A
three protein targeted proteomics assay can identify neuroendocrine
tumors with high sensitivity and specificity. The expanded use of this
technology may efficiently identify patients for optimal therapy.
About
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005206/en/
NANT
jhodson@nantworks.com
Source: